Scholarlink

Background <p>Hypertensive disorders of pregnancy (HDP) significantly increase the risk of maternal and perinatal morbidity. There is increasing evidence to support the use of newer biochemical markers like serum Corin and NT-proANP in hypertensive disorders of pregnancy.</p> Objective <p>To compare levels of serum NT-proANP and Corin in women with HDP versus normotensive pregnant women and to correlate maternal concentration of serum NT-proANP and Corin with severity of HDP, maternal and neonatal outcomes.</p> Methodology <p>This cross-sectional study compared maternal concentration of serum NT-proANP and Corin in women diagnosed as HDP versus normal controls.</p> Results <p>We recruited 90 women in the study, 45 women with preeclampsia and 45 normotensive controls. The levels of serum NT-proANP and Corin were significantly higher in women with hypertensive disorder of pregnancy as compared to control group. Women with severe disease had higher NT-proANP as compared to nonsevere preeclampsia and normotensive (3.18 ± 4.27–2.81 ± 1.93 vs. 1.90 ± 0.77 vs. 1.03 ± 0.54). The area under curve for prediction of maternal adverse outcomes with serum Corin and NT-proANP was found to be 0.653 and 0.747. The AUC (95% CI) for the Corin to predict adverse neonatal outcomes was 0.667 (0.554–0.781) while that for ProANP was 0.658 (0.542 − 0.774).</p> Conclusions <p>The levels of serum NT-proANP and corin were significantly increased in HDP and were associated with maternal and neonatal adverse events in HDP patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlation Between Serum Corin and N-Terminal Proatrial Natriuretic Peptide with Maternal and Neonatal Outcomes in Hypertensives Disorders of Pregnancy

  • 期刊论文

  • 发表日期：

    2025年11月3日

查看全文
  • Namrata Kumar,
  • Rupali Nayak,
  • Wahid Ali,
  • Armin Ahmad

摘要

Background

Hypertensive disorders of pregnancy (HDP) significantly increase the risk of maternal and perinatal morbidity. There is increasing evidence to support the use of newer biochemical markers like serum Corin and NT-proANP in hypertensive disorders of pregnancy.

Objective

To compare levels of serum NT-proANP and Corin in women with HDP versus normotensive pregnant women and to correlate maternal concentration of serum NT-proANP and Corin with severity of HDP, maternal and neonatal outcomes.

Methodology

This cross-sectional study compared maternal concentration of serum NT-proANP and Corin in women diagnosed as HDP versus normal controls.

Results

We recruited 90 women in the study, 45 women with preeclampsia and 45 normotensive controls. The levels of serum NT-proANP and Corin were significantly higher in women with hypertensive disorder of pregnancy as compared to control group. Women with severe disease had higher NT-proANP as compared to nonsevere preeclampsia and normotensive (3.18 ± 4.27–2.81 ± 1.93 vs. 1.90 ± 0.77 vs. 1.03 ± 0.54). The area under curve for prediction of maternal adverse outcomes with serum Corin and NT-proANP was found to be 0.653 and 0.747. The AUC (95% CI) for the Corin to predict adverse neonatal outcomes was 0.667 (0.554–0.781) while that for ProANP was 0.658 (0.542 − 0.774).

Conclusions

The levels of serum NT-proANP and corin were significantly increased in HDP and were associated with maternal and neonatal adverse events in HDP patients.